<PAGE> 1
SCHEDULE 14A INFORMATION
(Rule 14a-101)
PROXY STATEMENT PURSUANT TO SECTION 14(A) OF
THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )
Filed by the Registrant [X]
Filed by a Party other than the Registrant [ ]
Check the appropriate box:
[ ] Preliminary Proxy Statement
[ ] Confidential, for Use of the Commission Only
(as permitted by Rule 14a-6(e)(2))
[ ] Definitive Proxy Statement
[X] Definitive Additional Materials
[ ] Soliciting Material Pursuant to sec.240.14a-11(c) or sec.240.14a-12
AMYLIN PHARMACEUTICALS, INC.
--------------------------------------------------------------------------------
(Name of Registrant as Specified In Its Charter)
--------------------------------------------------------------------------------
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
[X] No fee required.
[ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.
(1) Title of each class of securities to which transaction applies:
(2) Aggregate number of securities to which transaction applies:
(3) Per unit price or other underlying value of transaction computed
pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the
filing fee is calculated and state how it was determined):
(4) Proposed maximum aggregate value of transaction:
(5) Total fee paid:
[ ] Fee paid previously with preliminary materials.
[ ] Check box if any part of the fee is offset as provided by Exchange Act Rule
0-11(a)(2) and identify the filing for which the offsetting fee was paid
previously. Identify the previous filing by registration statement number,
or the Form or Schedule and the date of its filing.
(1) Amount Previously Paid:
(2) Form, Schedule or Registration Statement No.:
(3) Filing Party:
(4) Date Filed:
<PAGE> 2
[AMYLIN LETTERHEAD]
VIA FACSIMILE (301)545-4800
January 19, 2001
Mr. Steven Sears
Institutional Shareholders Services
1455 Research Boulevard
Rockville, Maryland 20850
Dear Mr. Sears:
Per our discussion, Amylin Pharmaceuticals, by this letter, commits to the
following:
1. Without the prior approval of the company's shareholders, options issued
under any of the corporation's existing stock option plans will not be
repriced by lowering the option exercise price of a previously granted
award, or by cancellation of outstanding options with subsequent
replacement, or regrant of options with lower exercise prices, and that,
2. The plan will be amended at our next Board of Directors meeting to reflect
these clarifications and a copy of the change will be sent to ISS.
With this commitment, we ask that you revise your recommendation to a vote "FOR"
Item 1, "To Approve the Company's 2001 Equity Incentive Plan."
Thanks for your cooperation.
Best regards,
/s/ Joseph C. Cook, Jr.
Joseph C. Cook, Jr.
JCC/lab
